Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857678 | 1.00 | HRH2 (0.51) | HRH2SIGMAR1ACHEMC4RDRD2 | |
| SCHEMBL5692251 | 0.85 | HRH2 (0.66) | HRH2SIGMAR1ACHEMC4RLMNA | |
| SCHEMBL20284487 | 0.85 | HRH2 (0.66) | HRH2SIGMAR1ACHEMC4RLMNA | |
| SCHEMBL14528083 | 0.85 | HRH2 (0.66) | HRH2SIGMAR1ACHEMC4RLMNA | |
| SCHEMBL1309373 | 0.78 | HRH2 (0.52) | HRH2SIGMAR1ACHEMC4RLMNA | |
| SCHEMBL22699692 | 0.78 | CYP2D6 (0.35) | SIGMAR1 | |
| SCHEMBL25154769 | 0.77 | SIGMAR1 (0.55) | HRH2SIGMAR1ACHEMC4RDRD4 | |
| SCHEMBL14645859 | 0.77 | SIGMAR1 (0.68) | HRH2SIGMAR1 | |
| SCHEMBL1307217 | 0.76 | SIGMAR1 (0.69) | SIGMAR1ACHEMC4RDRD4LMNA | |
| SCHEMBL26428058 | 0.76 | HRH2 (0.50) | HRH2SIGMAR1ACHEMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-7087610-B2 | Benzothiazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005120508-A1 | BENZOTHIAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272734-A1 | Benzothiazole antiviral agents | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | HRH2 2268/4885SIGMAR1 4605/4885ACHE 3323/4885 |
| US-20050272734-A1 | Benzothiazole antiviral agents | ZC3HAV1, MAVS, SAMHD1 | HRH2 2485/4885SIGMAR1 2223/4885ACHE 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.